Demonstration of safety in Alzheimer's patients for intervention with an anti-hypertensive drug Nilvadipine: results from a 6-week open label study

被引:32
作者
Kennelly, S. P. [1 ,2 ]
Abdullah, L. [3 ]
Paris, D. [3 ]
Parish, J. [3 ]
Mathura, V. [3 ]
Mullan, M. [3 ]
Crawford, F. [3 ]
Lawlor, B. A. [1 ,2 ]
Kenny, R. A. [3 ]
机构
[1] St James Hosp, Dublin 8, Ireland
[2] Trinity Coll Dublin, Dublin, Ireland
[3] Roskamp Inst, Sarasota, FL USA
关键词
Alzheimer's; Nilvadipine; calcium; tolerability; anti-hypertensive; CALCIUM-CHANNEL BLOCKERS; BLOOD-PRESSURE; ORTHOSTATIC HYPOTENSION; SYSTOLIC HYPERTENSION; DOUBLE-BLIND; DEMENTIA; DISEASE; MILD; PREVENTION; RECOMMENDATIONS;
D O I
10.1002/gps.2638
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background: Nilvadipine may lower rates of conversion from mild-cognitive impairment to Alzheimer's disease (AD), in hypertensive patients. However, it remains to be determined whether treatment with nilvadipine is safe in AD patients, given the higher incidence of orthostatic hypotension (OH) in this population, who may be more likely to suffer from symptoms associated with the further exaggeration of a drop in BP. Objective: The aim of this study was to investigate the safety and tolerability of nilvadipine in AD patients. Methods: AD patients in the intervention group (n = 56) received nilvadipine 8 mg daily over 6-weeks, compared to the control group (n = 30) who received no intervention. Differences in systolic (SBP) and diastolic (DBP) blood pressure, before and after intervention, was assessed using automated sphygmo-manometer readings and ambulatory BP monitors (ABP), and change in OH using a finometer. Reporting of adverse events was monitored throughout the study. Results: There was a significant reduction in the SBP of treated patients compared to non-treated patients but no significant change in DBP. Individuals with higher initial blood pressure (BP) had greater reduction in BP but individuals with normal BP did not experience much change in their BP. While OH was present in 84% of the patients, there was no further drop in BP recorded on active stand studies. There were no significant differences in adverse event reporting between groups. Conclusion: Nilvadipine was well tolerated by patients with AD. This study supports further investigation of its efficacy as a potential treatment for AD. Copyright (C) 2010 John Wiley & Sons, Ltd.
引用
收藏
页码:1038 / 1045
页数:8
相关论文
共 36 条
[1]   Autonomic dysfunction in dementia [J].
Allan, L. M. ;
Ballard, C. G. ;
Allen, J. ;
Murray, A. ;
Davidson, A. W. ;
McKeith, I. G. ;
Kenny, R. A. .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2007, 78 (07) :671-677
[2]   The period of hypotension following orthostatic challenge is prolonged in dementia with Lewy bodies [J].
Andersson, M. ;
Hansson, O. ;
Minthon, L. ;
Ballard, C. G. ;
Londos, E. .
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2008, 23 (02) :192-198
[3]   PREVALENCE OF POSTURAL HYPOTENSION AT BASE-LINE IN THE SYSTOLIC HYPERTENSION IN THE ELDERLY PROGRAM (SHEP) COHORT [J].
APPLEGATE, WB ;
DAVIS, BR ;
BLACK, HR ;
SMITH, WM ;
MILLER, ST ;
BURLANDO, AJ .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1991, 39 (11) :1057-1064
[4]   Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252
[5]   CLINICAL PRESENTATION OF ORTHOSTATIC HYPOTENSION IN THE ELDERLY [J].
CRAIG, GM .
POSTGRADUATE MEDICAL JOURNAL, 1994, 70 (827) :638-642
[6]   Active and Passive Aβ-Immunotherapy: Preclinical and Clinical Studies and Future Directions: Part II [J].
Cribbs, David H. ;
Agadjanyan, Michael G. .
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2009, 8 (02) :82-87
[7]   EFFECT OF LONG-TERM ANTIHYPERTENSIVE THERAPY ON CARDIAC ANATOMY IN PATIENTS WITH ESSENTIAL-HYPERTENSION [J].
DRAYER, JIM ;
WEBER, MA ;
GARDIN, JM ;
LIPSON, JL .
AMERICAN JOURNAL OF MEDICINE, 1983, 75 (3A) :116-120
[8]   24 HOUR AMBULATORY BLOOD-PRESSURE PROFILE OF A NEW SLOW-RELEASE FORMULATION OF DILTIAZEM IN MILD TO MODERATE HYPERTENSION [J].
DUPONT, AG ;
COUPEZ, JM ;
JENSEN, P ;
COUPEZLOPINOT, R ;
SCHOORS, DF ;
HERMANNS, P ;
NICOLAS, M .
CARDIOVASCULAR DRUGS AND THERAPY, 1991, 5 (04) :701-707
[9]   Treatment options in Alzheimer's disease: Maximizing benefit, managing expectations [J].
Farlow, Martin R. ;
Miller, Michael L. ;
Pejovic, Vojislav .
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2008, 25 (05) :408-422
[10]  
FAUST G, 1992, J CARDIOVASC PHARM, V20, pS56